Table 2.

Predictors of early treatment discontinuation

Variable	Cohort 1a		Cohort 1b		Total, N	P
	N	%	N	%
Number of cases	60	37	102	63	162
Gender						.969
Male	41	68	70	69	111
Female	19	32	32	31	51
Age, years, median (range)	68.5 (40-81)		69.0 (41-82)			.1569
Age groups, years						.517
18-59	13	22	13	13	26
60-64	10	16	16	16	26
65-69	15	25	24	23	39
70-74	9	15	23	23	32
75	13	22	26	25	39
BMI						.0054
≤25	24	40	40	39	64
>25	17	28	49	48	66
Missing	19	32	13	13	32
Histology						.6805
Adenocarcinoma	39	65	63	62	102
Non-adenocarcinoma	21	35	39	38	60
Metastasis
>2 metastatic sites						.0504
Yes	20	33	20	20	40
No	40	67	82	80	122
Liver metastasis						.1666
Yes	14	23	15	15	29
No	46	77	87	85	133
Brain metastasis						.092
Yes	13	22	12	12	25
No	47	78	90	88	137
Smoking habits						.4917
Smoker	47	78	81	79	128
Nonsmoker	10	17	12	12	22
Missing	3	5	9	9	12
ECOG PS						.0132
0-1	41	68	82	80	123
2	8	13	2	2	10
Missing	11	18	18	18	29
Neutrophil/lymphocyte ratio (median)	3,65 (0.26-20.86)		2,42(0.13-17.23)			.0089
≤2.91	17	28	57	56	74	.0004
>2.91	34	57	27	26	61
Missing	9	15	18	18	27
Concomitant treatment
Antibiotics						.0012
Yes	30	50	46	45	76
No	11	18	43	42	54
Missing	19	32	13	13	32
Glucocorticoids						.0136
Yes	24	40	50	49	74
No	17	28	39	38	56
Missing	19	32	13	13	32

Cohort 1a = early treatment discontinuation (etd).

Cohort 1b = Not early treatment discontinuation (Not etd).

Values in bold are statistically significant.

Abbreviations: BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status PS.